Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7494948 | 0.82 | PTGS2 (0.65) | PTGS2PTGS1 | |
| SCHEMBL5208302 | 0.80 | PTGS2 (0.62) | PTGS2PTGS1 | |
| SCHEMBL7620854 | 0.79 | PTGS2 (0.67) | PTGS2PTGS1 | |
| SCHEMBL213125 | 0.79 | PTGS2 (0.80) | PTGS2PTGS1 | |
| SCHEMBL6966856 | 0.79 | PTGS2 (0.71) | PTGS2PTGS1 | |
| SCHEMBL6992349 | 0.78 | PTGS2 (0.68) | PTGS2PTGS1 | |
| SCHEMBL6514518 | 0.77 | PTGS2 (0.65) | PTGS2PTGS1 | |
| SCHEMBL3240080 | 0.77 | PTGS2 (0.81) | PTGS2PTGS1 | |
| SCHEMBL677786 | 0.77 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL7618276 | 0.77 | PTGS2 (0.81) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110914250-B | Novel process for synthesizing tilobaxib | 珂思玛股份公司 | 2023-06-27 | — | — | CN | claimed |
| CN-111201212-B | Synthesis method of feloxicib and intermediate thereof | 四川青木制药有限公司 | 2022-07-26 | — | — | CN | claimed |
| EP-3609877-B1 | PROCESS FOR THE SYNTHESIS OF FIROCOXIB | COSMA S P A (IT) | 2020-12-23 | — | — | EP | claimed |
| US-10807962-B2 | Process for the synthesis of firocoxib | COSMA S.P.A. (IT) | 2020-10-20 | — | — | US | claimed |
| CN-107686471-B | Synthesis method of feloxicib and intermediate thereof | 成都苑东生物制药股份有限公司 | 2020-07-03 | — | — | CN | claimed |
| CN-111201212-A | Synthesis method of feloxicib and intermediate thereof | 四川青木制药有限公司 | 2020-05-26 | — | — | CN | claimed |
| US-20200102279-A1 | NEW PROCESS FOR THE SYNTHESIS OF FIROCOXIB | COSMA S.P.A. (IT) | 2020-04-02 | — | — | US | claimed |
| CN-110914250-A | Novel process for synthesizing felicoxib | 珂思玛股份公司 | 2020-03-24 | — | — | CN | claimed |
| EP-3609877-A1 | NEW PROCESS FOR THE SYNTHESIS OF FIROCOXIB | Cosma S.p.A. (IT) | 2020-02-19 | — | — | EP | claimed |
| WO-2018188763-A1 | NEW PROCESS FOR THE SYNTHESIS OF FIROCOXIB | COSMA S.P.A. (IT) | 2018-10-18 | — | — | WO | claimed |
| CN-107686471-A | A kind of Fei Luokao former times and its synthetic method of intermediate | 四川青木制药有限公司 | 2018-02-13 | — | — | CN | claimed |
| CN-104803956-A | Synthesis method of firocoxib | Jiangsu tianhe pharmaceutical co ltd | 2015-07-29 | — | — | CN | claimed |
| CN-110914250-B | Novel process for synthesizing tilobaxib | 珂思玛股份公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-111201212-B | Synthesis method of feloxicib and intermediate thereof | 四川青木制药有限公司 | 2022-07-26 | — | — | CN | disclosed |
| EP-3609877-B1 | PROCESS FOR THE SYNTHESIS OF FIROCOXIB | COSMA S P A (IT) | 2020-12-23 | — | — | EP | disclosed |
| EP-3609877-B1 | PROCESS FOR THE SYNTHESIS OF FIROCOXIB | COSMA S P A (IT) | 2020-12-23 | — | — | EP | disclosed |
| EP-0863891-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-09-16 | — | — | EP | disclosed |
| US-5698584-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA, INC. (CA) | 1997-12-16 | — | — | US | disclosed |
| WO-1997016435-A1 | 3,4-DIARYL-2-HYDROXY-2,5-DIHYDROFURANS AS PRODRUGS TO COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-05-09 | — | — | WO | disclosed |
| WO-1997014691-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102279-A1 | NEW PROCESS FOR THE SYNTHESIS OF FIROCOXIB | PPOX, RIOX2, CYP4X1 | PTGS2 690/4885PTGS1 629/4885 |
| US-10807962-B2 | Process for the synthesis of firocoxib | RIOX2, PPOX, CYP4X1 | PTGS2 634/4885PTGS1 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.